Drug Profile

Psilocybin - COMPASS Pathways

Alternative Names: COMP-360; Psilocybine

Latest Information Update: 26 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator COMPASS Pathways
Developer COMPASS Pathways; Imperial College of Science, Technology and Medicine; Johns Hopkins University
Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Phase III Depressive disorders
Phase II Anorexia nervosa; Bipolar depression; Major depressive disorder; Post-traumatic stress disorders; Somatoform disorders
Phase Unknown Pervasive child development disorders

23 Jun 2025 COMPASS Pathways plans to discuss preliminary phase-III COMP005 trial data with US FDA
23 Jun 2025 Interim adverse events and efficacy data from the phase-III COMP005 trial in Depressive disorders released by COMPASS Pathways
26 Mar 2025 Compass Pathways completes enrolment of patients in phase-III COMP005 trials in Depressive disorders (Treatment-resistant) in United Kingdom (PO) (NCT05624268)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com